

09/806842

## SEQUENCE LISTING

<110> Eliezer Masliah  
 <120> METHODS FOR TESTING AND SELECTION OF INHIBITORS  
 WITH ANTI-AMYLOIDOGENIC ACTIVITIES FOR THE  
 TREATMENT OF NEURODEGENERATIVE DISEASE  
 <130> 6627-9013  
 <140> unknown  
 <141> October 6, 1999  
 <150> US 60/103,310  
 <151> October 6, 1998  
 <160> 8  
 <170> Word Perfect 8.1

<210> 1  
 <211> 30  
 <212> ssDNA  
 <213> Artificial Sequence

<220> encoding amino acids 1-7 of human  $\beta$ -synuclein containing an  
 NdeI site at its 5' end  
 <221> PCR primer  
 <222> 1...30  
 <223> BSYNNDE

<400> 1  
 ggattccata    tggacgtgtt    catgaagggc    30

<210> 2  
 <211> 54  
 <212> ssDNA  
 <213> Artificial Sequence

<220> amino acids 73-83 of human NACP/ $\alpha$ -synuclein and amino  
 acids 66-72 of human  $\beta$ -synuclein  
 <221> PCR primer  
 <222> 1...54  
 <223> anti-sense

<400> 2  
 ctccactgtc    ttctgggcta    ctgctgtcac    accagagaac    acagctcctc    50  
 ccag    54

<210> 3

<211> 55  
 <212> ssDNA  
 <213> Artificial Sequence  
  
 <220> encoding amino acids 73-83 of human NACP/ $\alpha$ -synuclein  
 and amino acids 73-79 of human  $\beta$ -synuclein  
 <221> PCR primer  
 <222> 1...55  
 <223> sense  
  
 <400> 3  
 ggtgtgacag cagtagccca gaagacagtg gagggggcag ggaacatcgc 50  
 agcag 55  
  
  
 <210> 4  
 <211> 34  
 <212> ssDNA  
 <213> Artificial Sequence  
  
 <220> amino acids 129-134 of human  $\beta$ -synuclein containing an  
 NotI site at its 5' end  
 <221> PCR primer  
 <222> 1...34  
 <223> BSYNNOT  
  
 <400> 4  
 agatcgcggc cgcttacgcc tctggctcat actc 34  
  
  
 <210> 5  
 <211> 54  
 <212> ssDNA  
 <213> Artificial Sequence  
  
 <220> amino acids 63-72 of human NACP/ $\alpha$ -synuclein and amino  
 acids 55-62 of human  $\beta$ -synuclein  
 <221> PCR primer  
 <222> 1...54  
 <223> anti-sense  
  
 <400> 5  
 cgtcaccact gctcctccaa catttgtcac ctgttccttg gtttttcag 50  
 ccac 54  
 <210> 6

<211>	51		
<212>	ssDNA		
<213>	Artificial Sequence		
<220>	encoding amino acids 63-79 of human NACP/ $\alpha$ -synuclein		
<221>	PCR primer		
<222>	1...51		
<223>	sense		
<400>	6		
gtgacaaatg	ttggaggagc	agtggtgacg	ggtgtgacag cagtagccca 50
g	51		
<210>	7		
<211>	24		
<212>	ssDNA		
<213>	Artificial Sequence		
<220>	genomic DNA from transgenic mouse tail		
<221>	PCR primer		
<222>	1...24		
<223>	sense		
<400>	7		
ccagcggccg	ctctagaact	agtg	24
<210>	8		
<211>	25		
<212>	ssDNA		
<213>	Artificial Sequence		
<220>	genomic DNA from transgenic mouse tail		
<221>	PCR primer		
<222>	1...25		
<223>	anti-sense		
<400>	8		
ccagtcgacc	ggtcattggct	gcgcc	25
<210>	9		
<211>	24		
<212>	PRT		
<213>	Artificial Sequence		

<220> residues 101-124 of NACP/ $\alpha$ -synuclein  
 <221> synthetic peptide  
 <222> 1...24  
 <223> polyclonal antibody target

<400> 9  
 Gly - Lys - Gly - Glu - Glu - Gly - Tyr - Pro - Asp - Glu - Gly - Ile - Leu -  
 1 5 10  
 Glu - Asp - Met - Pro - Val - Asp - Pro - Gly - Ser - Glu - Ala  
 15 20

<210> 10  
 <211> 140  
 <212> PRT  
 <213> NACP alpha-synuclein; Mus musculus

<220>  
 <221> protein sequence  
 <222> 1...140

<400> 10  
 Met-Asp-Val-Phe-Met-Lys-Gly-Leu-Ser-Lys-Ala-Lys-Glu-Gly-Val-Val-Ala  
 1 5 10 15  
 Ala-Ala-Glu-Lys-Thr-Lys-Gln-Gly-Val-Ala-Glu-Ala-Ala-Gly-Lys-Thr-Lys  
 20 25 30  
 Glu-Gly-Val-Leu-Tyr-Val-Gly-Ser-Lys-Thr-Lys-Glu-Gly-Val-Val-His-Gly  
 35 40 45 50  
 Val-Thr-Thr-Val-Ala-Glu-Thr-Thr-Lys-Glu-Gln-Val-Thr-Asn-Val-Gly-Gly  
 55 60 65  
 Ala-Val-Val-Thr-Gly-Val-Thr-Ala-Val-Ala-Gln-Lys-Thr-Val-Glu-Gly-Ala  
 70 75 80 85  
 Gly-Asn-Ile-Ala-Ala-Ala-Thr-Gly-Phe-Val-Lys-Lys-Asp-Gln-Met-Gly  
 90 95 100  
 Lys-Gly-Glu-Glu-Gly-Tyr-Pro-Gln-Glu-Gly-Ile-Leu-Glu-Asp-Met-Pro  
 105 110 115  
 Val-Asp-Pro-Gly-Ser-Glu-Ala-Tyr-Glu-Met-Pro-Ser-Glu-Glu-Gly-Tyr  
 120 125 130  
 Gln-Asp-Tyr-Glu-Pro-Glu-Ala  
 135 140